<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.106174</article-id><article-id pub-id-type="publisher-id">ACM-36310</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200600000_57880104.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  连花清瘟胶囊联合干扰素α-2b治疗新冠肺炎康复期病人的临床疗效研究
  Clinical Study on Treatment of COVID-19 in Convalescent Period Treated with Lianhua Qingwen Capsule Combined with Interferon α-2b
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>江建</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>亚林</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>富刚</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>旭</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>耀隆</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>汪</surname><given-names>双</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>贵州省职工医院脑科诊疗中心，贵州 贵阳</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>29</day><month>05</month><year>2020</year></pub-date><volume>10</volume><issue>06</issue><fpage>1144</fpage><lpage>1149</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨连花清瘟胶囊联合干扰素α-2b治疗新冠肺炎康复期病人的临床疗效研究。方法：选取我院收治的70例新冠肺炎康复期病人，随机分为对照组和观察组，每组35例。对照组采用阿比多尔+干扰素α-2b治疗，观察组采用连花清瘟颗粒联合干扰素α-2b治疗，对比两组患者的临床疗效、CT检查结果以及治疗前后的临床症状得分。结果：对照组患者的总有效率为68.57%，出院率为11.42%，CT疗效的总有效率率为62.86%，观察组的中患者的总有效率94.29%，出院率为42.86%，CT疗效的总有效率为85.71%，观察组患者的临床疗效的总有效率、CT疗效的总有效率以及出院率明显高于对照组(P &lt; 0.05)。治疗前，两组患者的临床症状得分比较无显著差异(P &gt; 0.05)。治疗后，两组患者的临床症状得分明显低于治疗前，观察组的临床症状得分明显低于对照组(P &lt; 0.05)。结论：连花清瘟胶囊联合干扰素α-2b治疗新冠肺炎康复期病人的疗效显著，可有效降低临床症状，提高出院率。
    Objective: To analyze the clinical effect of COVID-19 in convalescent period treated by Lianhua Qingwen capsule combined with Interferon α-2b. Methods: 70 patients with COVID-19 in convalescent period were randomly divided into control group and study group, 35 cases in each group. The control group was treated with arbidol combined with Interferon α-2b, and the study group was treated with Lianhua Qingwen capsule combined with Interferon α-2b. The clinical efficacy, CT findings and clinical symptom scores before and after treatment were compared between the two groups. Results: The total effective rate of the control group was 68.57%, the discharge rate was 11.42%, the total effective rate of CT effect was 62.86%, the total effective rate of the observation group was 94.29%, the discharge rate was 42.86%, and the total effective rate of CT effect was 85.71%. The total effective rate of clinical effect, CT effect and discharge rate in the observation group were significantly higher than those in the control group (P &lt; 0.05). Before treatment, there was no significant difference in clinical symptom scores between the two groups (P &gt; 0.05). After treatment, the clinical symptom scores of the two groups were significantly lower than that before treatment, and the clinical symptom scores of the observation group were significantly lower than that of the control group (P &lt; 0.05). Conclusion: The therapeutic effect of Lianhua Qingwen capsule combined with Interferon α-2b on COVID-19 in convalescent period is significant, which can effectively reduce the clinical symptoms and improve the discharge rate. 
  
 
</p></abstract><kwd-group><kwd>连花清瘟颗粒，干扰素α-2b，新冠肺炎, Lianhua Qingwen Capsule</kwd><kwd> Interferon α-2b</kwd><kwd> COVID-19</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>连花清瘟胶囊联合干扰素α-2b治疗新冠肺炎康复期病人的临床疗效研究<sup> </sup></title><p>陈江建，周亚林<sup>*</sup>，陈富刚，刘旭，陈耀隆，汪双</p><p>贵州省职工医院脑科诊疗中心，贵州 贵阳</p><disp-formula id="hanspub.36310-formula45"><graphic xlink:href="//html.hanspub.org/file/44-1571324x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年6月1日；录用日期：2020年6月22日；发布日期：2020年6月29日</p><disp-formula id="hanspub.36310-formula46"><graphic xlink:href="//html.hanspub.org/file/44-1571324x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨连花清瘟胶囊联合干扰素α-2b治疗新冠肺炎康复期病人的临床疗效研究。方法：选取我院收治的70例新冠肺炎康复期病人，随机分为对照组和观察组，每组35例。对照组采用阿比多尔+干扰素α-2b治疗，观察组采用连花清瘟颗粒联合干扰素α-2b治疗，对比两组患者的临床疗效、CT检查结果以及治疗前后的临床症状得分。结果：对照组患者的总有效率为68.57%，出院率为11.42%，CT疗效的总有效率率为62.86%，观察组的中患者的总有效率94.29%，出院率为42.86%，CT疗效的总有效率为85.71%，观察组患者的临床疗效的总有效率、CT疗效的总有效率以及出院率明显高于对照组(P &lt; 0.05)。治疗前，两组患者的临床症状得分比较无显著差异(P &gt; 0.05)。治疗后，两组患者的临床症状得分明显低于治疗前，观察组的临床症状得分明显低于对照组(P &lt; 0.05)。结论：连花清瘟胶囊联合干扰素α-2b治疗新冠肺炎康复期病人的疗效显著，可有效降低临床症状，提高出院率。</p><p>关键词 :连花清瘟颗粒，干扰素α-2b，新冠肺炎</p><disp-formula id="hanspub.36310-formula47"><graphic xlink:href="//html.hanspub.org/file/44-1571324x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/44-1571324x8_hanspub.png" /> <img src="//html.hanspub.org/file/44-1571324x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>自2020年1月7日起，世界卫生组织将新型冠状病毒命名为2019-nCoV，并证实人传人的特点 [<xref ref-type="bibr" rid="hanspub.36310-ref1">1</xref>]，已为全世界严重的突发公共卫生事件。目前新型冠状病毒肺炎(COVID-19)的临床症状主要表现为发热、干咳，乏力、并伴有咽干咽痛、鼻塞、流涕等症状，少数伴有腹泻现象，严重者可出现呼吸窘迫综合征，甚至出现脓毒症休克等 [<xref ref-type="bibr" rid="hanspub.36310-ref2">2</xref>]，目前暂时无特效治疗药物。随着COVID-19康复者越来越多，其康复期患者的治疗亦提上日程。目前关于COVID-19康复期的相关治疗方案可参考资料较少。中医药辨证治疗方案不仅在病毒性感染疾病中的防治方面具有一定的优势，而且对康复期的治疗依然有效 [<xref ref-type="bibr" rid="hanspub.36310-ref3">3</xref>]。COVID-19属中医属“疫”病范畴，是感受邪湿疫毒而发病 [<xref ref-type="bibr" rid="hanspub.36310-ref4">4</xref>]。康复期以气阴两虚、肺脾不足为主，治疗亦清热解毒，补气养阴，宣肺祛湿。连花清瘟胶囊具有清瘟解毒、宣肺泄热之功效。本研究采用连花清瘟颗粒联合干扰素α-2b治疗COVID-19康复患者，取得显著疗效，先报到如下。本研究通过本院伦理文员会的伦理许可(201912C04)。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 基本资料</title><p>随机选取2020年2月28日~2020年3月31日我院收治的70例新型冠状病毒肺炎出院后再集中隔离医学观察(2~4周)的患者(我们称为新冠肺炎康复期患者)，均符合《新型冠状病毒肺炎诊疗方案(试行七版)》 [<xref ref-type="bibr" rid="hanspub.36310-ref5">5</xref>] 诊断标准及出院标准，且均给予CT确诊。随机分为对照组和研究组，每组35例。其中男38例，女32例，年龄21~65岁，平均年龄(44.95 &#177; 4.63)岁，发病时间2~15 d，平均发病时间(7.26 &#177; 2.19) d，伴有高血压16例，冠心病13例，糖尿病7例，其他慢性疾病3例。两组患者的基本情况比较无显著性差异，具有可比性(P &gt; 0.05)。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of basic conditions between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  rowspan="2"  >男/女</th><th align="center" valign="middle"  rowspan="2"  >平均年龄</th><th align="center" valign="middle"  rowspan="2"  >平均发病时间</th><th align="center" valign="middle"  colspan="4"  >伴有疾病</th></tr></thead><tr><td align="center" valign="middle" >高血压</td><td align="center" valign="middle" >冠心病</td><td align="center" valign="middle" >糖尿病</td><td align="center" valign="middle" >其他</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >20/15</td><td align="center" valign="middle" >45.21 &#177; 4.68</td><td align="center" valign="middle" >7.18 &#177; 2.16</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >18/17</td><td align="center" valign="middle" >44.75 &#177; 4.92</td><td align="center" valign="middle" >7.50 &#177; 2.42</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2</td></tr></tbody></table></table-wrap><p>表1. 两组患者的基本情况比较</p></sec><sec id="s4_2"><title>2.2. 方法</title><p>对照组给予阿比多尔(石家庄四药有限公司，批号：20190913)，0.2 g/次，2次/d，雾化干扰素α-2b (北京瑞得合通药业有限公司，批号：20191108)，600万U，2次/d，连续治疗15 d。</p><p>观察组给予连花清瘟胶囊(北京以岭药业有限公司，批号：B1907008)，1.4 g/次，2次/d，雾化干扰素α-2b，600万U，2次/d，连续治疗15 d。</p></sec><sec id="s4_3"><title>2.3. 疗效标准</title><p>根据《中药新药临床研究指导原则(试行)》 [<xref ref-type="bibr" rid="hanspub.36310-ref6">6</xref>] 制订标准，显效：症状体征明显减轻或大部分消失，临床症状总积分减少≥70%；有效：症状体征减轻，30%≤临床症状总积分减少&lt;70%；无效：症状体征无好转或加重，临床症状总积分减少&lt;30%。有效率=(显效+有效)/例数&#215;100%。临床症状评分见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Clinical symptom scal</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >症状</th><th align="center" valign="middle" >0</th><th align="center" valign="middle" >2分</th><th align="center" valign="middle" >4分</th><th align="center" valign="middle" >6分</th></tr></thead><tr><td align="center" valign="middle" >发热</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >37.3℃~38.2℃</td><td align="center" valign="middle" >≤39.0℃</td><td align="center" valign="middle" >&gt;39.0℃</td></tr><tr><td align="center" valign="middle" >咳嗽</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >偶尔</td><td align="center" valign="middle" >阵作</td><td align="center" valign="middle" >连声频作</td></tr><tr><td align="center" valign="middle" >咽干咽痛</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >轻微</td><td align="center" valign="middle" >疼痛，偶欲饮水</td><td align="center" valign="middle" >剧痛，频频饮水</td></tr><tr><td align="center" valign="middle" >胸闷气促</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >轻微</td><td align="center" valign="middle" >明显但不影响活动</td><td align="center" valign="middle" >明显影响活动</td></tr><tr><td align="center" valign="middle" >乏力</td><td align="center" valign="middle" >无</td><td align="center" valign="middle" >不影响活动</td><td align="center" valign="middle" >活动减少</td><td align="center" valign="middle" >不欲活动</td></tr></tbody></table></table-wrap><p>表2. 临床症状评分量表</p></sec><sec id="s4_4"><title>2.4. CT检测</title><p>根据《新型冠状病毒肺炎影像学辅助诊断指南》 [<xref ref-type="bibr" rid="hanspub.36310-ref7">7</xref>] 制定CT检查标准，基本吸收：肺部病变消失≥70%；好转：肺部病变减少≥30%；无变化：肺部病变基本无变化；加重：肺部病变加重≥30%。有效率=(基本吸收+好转)/例数&#215;100%。</p></sec><sec id="s4_5"><title>2.5. 统计学处理</title><p>所得数据应用SPSS17.0软件进行分析，计量资料以均数&#177;标准差 ( X &#175; &#177; S ) 表示，采用t检验，计数资料以例数百分比表示，应用c<sup>2</sup>检验，P &lt; 0.05为差异具有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 两组临床疗效比较</title><p>对照组患者的总有效率为68.57%，出院率为11.42%，观察组的中患者的总有效率94.29%，出院率为42.86%，两组患者的总有效率和出院率比较具有显著差异(P &lt; 0.05)。见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of treatment effect between the two groups (cases, %</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >显效</th><th align="center" valign="middle" >有效</th><th align="center" valign="middle" >无效</th><th align="center" valign="middle" >总有效率</th><th align="center" valign="middle" >出院率</th></tr></thead><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >33 (94.29)<sup>2)</sup></td><td align="center" valign="middle" >15 (42.86)<sup>2)</sup></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >24 (68.57)</td><td align="center" valign="middle" >4 (11.42)</td></tr></tbody></table></table-wrap><p>表3. 两组治疗效果比较(例，%)</p><p>注：与对照组比较，<sup>2)</sup>P &lt; 0.05。</p></sec><sec id="s5_2"><title>3.2. 两组治疗后胸部CT疗效比较</title><p>对照组患者的胸部CT疗效的总有效率率为62.86%，观察组患者的胸部CT疗效的总有效率率为85.71%，观察组患者的胸部CT疗效的总有效率率明显高于对照组(P &lt; 0.05)。见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Treatment effect comparison between the two groups (cases, %</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >基本吸收</th><th align="center" valign="middle" >好转</th><th align="center" valign="middle" >无变化</th><th align="center" valign="middle" >加重</th><th align="center" valign="middle" >总有效率</th></tr></thead><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2 (5.71)</td><td align="center" valign="middle" >30 (85.71)<sup>2)</sup></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >6 (17.14)</td><td align="center" valign="middle" >22 (62.86)</td></tr></tbody></table></table-wrap><p>表4. 两组治疗效果比较(例，%)</p><p>注：与对照组比较，<sup>2)</sup>P &lt; 0.05。</p></sec><sec id="s5_3"><title>3.3. 两组患者治疗前后临床症状得分比较</title><p>两组患者治疗前的发热、咳嗽、胸闷气促、咽干咽痛以及乏力等临床症状得分比较无显著性差异(P &lt; 0.05)。与治疗前比较，两组患者的临床症状得分明显降低，两组患者间的临床症状得分比较具有显著性差异(P &lt; 0.05)。见表5。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Comparison of clinical symptom scores between the two groups (score, ( X &#175; &#177; S ) </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >发热</th><th align="center" valign="middle" >咳嗽</th><th align="center" valign="middle" >胸闷气促</th><th align="center" valign="middle" >咽干咽痛</th><th align="center" valign="middle" >乏力</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >观察组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >2.67 &#177; 0.36</td><td align="center" valign="middle" >4.48 &#177; 0.76</td><td align="center" valign="middle" >2.83 &#177; 0.69</td><td align="center" valign="middle" >4.75 &#177; 0.65</td><td align="center" valign="middle" >4.65 &#177; 1.26</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >0.57 &#177; 0.10<sup>1,2)</sup></td><td align="center" valign="middle" >1.59 &#177; 0.45<sup>1,2)</sup></td><td align="center" valign="middle" >1.21 &#177; 0.45<sup>1,2)</sup></td><td align="center" valign="middle" >1.56 &#177; 0.51<sup>1,2)</sup></td><td align="center" valign="middle" >1.81 &#177; 0.91<sup>1,2)</sup></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >对照组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >2.72 &#177; 0.48</td><td align="center" valign="middle" >4.54 &#177; 0.82</td><td align="center" valign="middle" >2.85 &#177; 0.52</td><td align="center" valign="middle" >4.68 &#177; 0.86</td><td align="center" valign="middle" >4.71 &#177; 1.32</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >1.11 &#177; 0.63<sup>1)</sup></td><td align="center" valign="middle" >2.70 &#177; 0.41<sup>1)</sup></td><td align="center" valign="middle" >1.72 &#177; 0.09<sup>1)</sup></td><td align="center" valign="middle" >2.18 &#177; 0.26<sup>1)</sup></td><td align="center" valign="middle" >1.19 &#177; 0.59<sup>1)</sup></td></tr></tbody></table></table-wrap><p>表5. 两组患者临床症状得分比较(分， ( X &#175; &#177; S ) )</p><p>注：与治疗前比较，<sup>1)</sup> P &lt; 0.05，与对照组比较，<sup>2)</sup> P &lt; 0.05。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>COVID-19由冠状病毒(SARS-Cov-2)引起的肺炎，传播途径主要为飞沫、粪口等多个途径，具有传播快、传染性强，传染范围广等特点 [<xref ref-type="bibr" rid="hanspub.36310-ref8">8</xref>]，各年龄层人群均有易感性，已被定为乙类传染病，按甲类传染病管理 [<xref ref-type="bibr" rid="hanspub.36310-ref9">9</xref>]。随着国内疫情变化，COVID-19康复期的治疗既是对此次疫情的收尾工作，也是中医药事业在疾病的防治中重要作用的体现 [<xref ref-type="bibr" rid="hanspub.36310-ref10">10</xref>]。α-2b是干扰素 一种机体合成的干扰病毒复制的生物制剂，可使未感染的细胞免于感染，并且在抗病毒的同时提高患者免疫力 [<xref ref-type="bibr" rid="hanspub.36310-ref11">11</xref>]。雾化吸入可使干扰素α-2b直达病灶，增加局部药物浓度，阻止病毒扩散。阿比多尔是一种合成的广谱抗病毒药物 [<xref ref-type="bibr" rid="hanspub.36310-ref12">12</xref>]，通过嵌入细胞膜脂抑制多种DNA/RNA和包膜/非包膜病毒活性。用于抗流感病毒的预防和治疗，包括甲型、乙型流感以及流感并发症。</p><p>COVID-19属中医“瘟疫”范畴，病位在肺脾，病机以“湿、毒、虚”为主，根据疾病传变规律，分期辨证论治，康复期已呈虚多实少，但仍以治毒为主 [<xref ref-type="bibr" rid="hanspub.36310-ref13">13</xref>]，治疗亦清热解毒，补气祛瘀，利湿。连花清瘟方由银翘散和麻杏石甘汤化裁而来，具有广谱抗病毒作用。银翘散辛凉透表，清热解毒；麻杏石甘汤辛凉宣肺，清热平喘。大黄通腑泻热泄肺，截断病势；配伍红景天清肺化瘀，调节免疫；藿香芳香宣透化湿，辟秽逐邪；贯众、板蓝根、鱼腥草清热解毒；诸药合用清瘟解毒、宣肺泄热。研究证实，连花清瘟颗粒治疗COVID-19患者临床效果良好，可明显改善临床症状，降低轻症向重症转移比例。</p><p>本研究结果显示，观察组患者的临床疗效的总有效率、CT疗效的总有效率以及出院率明显高于对照组。提示连花清瘟胶囊联合干扰素α-2b治疗新冠肺炎康复期病人的疗效显著，可降低CT的肺部病变情况。与对照组相比，观察组患者治疗后的临床症状得分明显降低。提示连花清瘟胶囊联合干扰素α-2b治疗新冠肺炎康复期病人的可明显改善患者临床症状。</p><p>综上所述，连花清瘟胶囊联合干扰素α-2b治疗新冠肺炎康复期病人的疗效显著，可有效降低临床症状，提高出院率。</p></sec><sec id="s7"><title>文章引用</title><p>陈江建,周亚林,陈富刚,刘 旭,陈耀隆,汪 双. 连花清瘟胶囊联合干扰素α-2b治疗新冠肺炎康复期病人的临床疗效研究Clinical Study on Treatment of COVID-19 in Convalescent Period Treated with Lianhua Qingwen Capsule Combined with Interferon α-2b[J]. 临床医学进展, 2020, 10(06): 1144-1149. https://doi.org/10.12677/ACM.2020.106174</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.36310-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">凌晓颖, 陶嘉磊, 孙逊, 袁斌. 基于网络药理学探讨连花清瘟方抗冠状病毒的物质基础及机制研究[J/OL]. 中草药. http://kns.cnki.net/kcms/detail/12.1108.R.20200320.1650.006.html</mixed-citation></ref><ref id="hanspub.36310-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">傅晓霞, 林路平, 谭行华. 透解祛瘟颗粒治疗新型冠状病毒肺炎临床观察[J/OL]. 中国实验方剂学杂志.  
&lt;br&gt;https://doi.org/10.13422/j.cnki.syfjx.20201314</mixed-citation></ref><ref id="hanspub.36310-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">吴海洋, 吴军豪. 基于朱丹溪学术思想探讨新型冠状病毒肺炎康复期的中医治疗[J/OL]. 中医学报.  
http://kns.cnki.net/kcms/detail/41.1411.R.20200303.2212.007.html</mixed-citation></ref><ref id="hanspub.36310-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">贾振华. 络病理论指导新型冠状病毒肺炎证治探讨[J/OL]．中国实验方剂学杂志.  
&lt;br&gt;https://doi.org/10.13422/j.cnki.syfjx.20201146</mixed-citation></ref><ref id="hanspub.36310-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第七版) [EB/OL].  
http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm</mixed-citation></ref><ref id="hanspub.36310-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">王法财, 沈炳香, 何春远, 赵为陈, 聂松柳. 连花清瘟颗粒对新型冠状病毒肺炎的临床疗效及其机制的网络药理学研究[J/OL]. 中药药理与临床. &lt;br&gt;https://doi.org/10.13412/j.cnki.zyyl.20200318.001</mixed-citation></ref><ref id="hanspub.36310-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">国家卫健委. 世卫: 新型冠状病毒感染的肺炎疫情构成国际关注的突发公共卫生事件[EB/OL].  
http://www.nhc.gov.cn/xcs/s3574/202002/3fdf885083e5470090728ede3c7f7e4b.shtml</mixed-citation></ref><ref id="hanspub.36310-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">中国研究型医院学会感染与炎症放射学专业委员会. 新型冠状病毒肺炎影像学辅助诊断指南[J]. 中国医学影像技术, 2020, 36(3): 1-11.</mixed-citation></ref><ref id="hanspub.36310-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">王饶琼, 杨思进, 谢春光, 等. 清肺排毒汤治疗新型冠状病毒肺炎的临床疗效观察[J/OL]. 中药药理与临床.  
&lt;br&gt;https://doi.org/10.13412/j.cnki.zyyl.20200303.002</mixed-citation></ref><ref id="hanspub.36310-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">裴银辉, 张杰. 对新型冠状病毒肺炎康复期核酸检测阳性的认识[J/OL]. 医学争鸣.  
http://kns.cnki.net/kcms/detail/61.1481.r.20200330.1957.002.html</mixed-citation></ref><ref id="hanspub.36310-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">胡凤阳. 雾化吸入重组人干扰素α-2b联合布地奈德治疗毛细支气管炎患儿的疗效[J]. 医疗装备, 2019, 32(22): 91-92.</mixed-citation></ref><ref id="hanspub.36310-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">肖琦, 蒋茵婕, 吴思思, 汪洋, 安俊, 徐武平, 吴晶晶. 中药疏风解毒胶囊联合阿比多尔治疗轻症新型冠状病毒肺炎的价值分析[J/OL]. 中国中医急症. http://kns.cnki.net/kcms/detail/50.1102.R.20200309.1528.004.html</mixed-citation></ref><ref id="hanspub.36310-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">张萌萌, 吴琪, 张新雪, 赵宗江. 基于《瘟疫论》理论探讨新冠肺炎的辨证施治方法[J/OL]. 中国实验方剂学杂志. &lt;br&gt;https://doi.org/10.13422/j.cnki.syfjx.20201327</mixed-citation></ref></ref-list></back></article>